Eurofins Scientific SE Stock Swiss Exchange
Stocks
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 13.02B 14.66B 12.18B 11.1B 20.89B 1,411B 21.18B 147B 57.02B 719B 55.04B 53.84B 2,309B | P/E 2026 * |
25x | P/E 2027 * | 19.8x |
|---|---|---|---|---|---|
| Enterprise Value | 16.39B 18.45B 15.32B 13.96B 26.29B 1,776B 26.65B 185B 71.76B 905B 69.26B 67.76B 2,906B | EV / Sales 2026 * |
2.17x | EV / Sales 2027 * | 2.02x |
| Free-Float |
60.39% | Yield 2026 * |
1.07% | Yield 2027 * | 1.21% |
Last Transcript: Eurofins Scientific SE
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 1986-12-31 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 2014-12-31 |
Christian Wurst
PRN | Corporate Officer/Principal | 54 | 2019-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 1986-12-31 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 2014-12-31 |
Valérie Hanote
BRD | Director/Board Member | 60 | 1989-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 14.79B | |
| +4.16% | -0.36% | +49.37% | +94.17% | 74.46B | |
| -0.61% | +0.81% | +27.25% | +80.21% | 60.14B | |
| -2.54% | -1.65% | +4.86% | +33.32% | 48.15B | |
| -2.24% | -4.49% | +28.89% | +35.48% | 44.25B | |
| +1.81% | +4.65% | +356.08% | +699.24% | 43.99B | |
| -0.96% | +0.34% | +7.76% | +102.34% | 41.61B | |
| +3.32% | +3.49% | +11.18% | +51.23% | 29.97B | |
| +4.77% | +6.16% | +36.77% | +22.78% | 29.31B | |
| -2.70% | -8.72% | -24.66% | +337.35% | 24.93B | |
| Average | +0.48% | +1.97% | +55.28% | +161.79% | 44.09B | |
| Weighted average by Cap. | +0.63% | +1.83% | +59.51% | +152.83% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.53B 8.48B 7.05B 6.42B 12.09B 817B 12.25B 85.24B 33B 416B 31.85B 31.16B 1,336B | 7.94B 8.94B 7.43B 6.77B 12.74B 861B 12.92B 89.85B 34.78B 438B 33.57B 32.84B 1,408B |
| Net income | 531M 598M 496M 452M 852M 57.55B 863M 6.01B 2.33B 29.31B 2.24B 2.2B 94.14B | 660M 743M 617M 562M 1.06B 71.51B 1.07B 7.46B 2.89B 36.42B 2.79B 2.73B 117B |
| Net Debt | 3.37B 3.79B 3.15B 2.87B 5.4B 365B 5.47B 38.08B 14.74B 186B 14.23B 13.92B 597B | 3.03B 3.42B 2.84B 2.59B 4.87B 329B 4.93B 34.32B 13.29B 167B 12.82B 12.55B 538B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
